Exelixis Begins Phase 3 Pivotal Trial Of Cabozantinib In Patients With MRCC NASDAQ (RTTNews.com) - Exelixis Inc. ( EXEL ) announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma or mRCC who have experienced disease progression following treatment ... |
